Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.